The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration

Hulya Gungel,1 Ozen Ayranci Osmanbasoglu,1 Cigdem Altan,2 Deniz Oygar Baylancicek,3 Isil Basgil Pasaoglu2 1Istanbul Education and Research Hospital, Eye Clinic, 2Beyoglu Eye Education and Research Hospital, 3Kudret Eye Hospital, Istanbul, Turkey Aim: The objective of the study reported here was t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gungel H, Osmanbasoglu OA, Altan C, Baylancicek DO, Pasaoglu IB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/59bab0f174834088b532509789749b02
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:59bab0f174834088b532509789749b02
record_format	dspace
spelling	oai:doaj.org-article:59bab0f174834088b532509789749b022021-12-02T11:16:33ZThe effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration1177-5483https://doaj.org/article/59bab0f174834088b532509789749b022014-05-01T00:00:00Zhttp://www.dovepress.com/the-effects-of-ranibizumab-injections-on-fluorescein-angiographic-find-a16889https://doaj.org/toc/1177-5483 Hulya Gungel,1 Ozen Ayranci Osmanbasoglu,1 Cigdem Altan,2 Deniz Oygar Baylancicek,3 Isil Basgil Pasaoglu2 1Istanbul Education and Research Hospital, Eye Clinic, 2Beyoglu Eye Education and Research Hospital, 3Kudret Eye Hospital, Istanbul, Turkey Aim: The objective of the study reported here was to evaluate the effect of ranibizumab on retinal circulation times and vessel caliber and to analyze the correlation of these factors with visual acuity (VA) prognosis in patients with age-related macular degeneration (AMD).Subjects and methods: This prospective cohort study included 52 eyes of 46 patients (mean age 73.5 years [standard deviation 7.7]; 28 males, 18 females). The study parameters were best-corrected visual acuity (BCVA), central macular thickness (CMT) (pre- and posttreatment: for 3 months after the last injection), retinal circulation times, diameter of retinal arteriole (DRA), and diameter of retinal vein (DRV) (pre- and posttreatment: after a loading dose of three consecutive injections of ranibizumab with a 4-week interval in the initial phase). The pretreatment, posttreatment measurements, and their differences were recorded for analyses. The injections were repeated when needed. Eyes were grouped into one of two groups according to VA recovery: Group 1, cases showing significant recovery of VA (n=21, 37%), and Group 2, cases showing preservation of VA (n=22, 42%) and deterioration of VA (n=11, 21%). Differences were compared statistically in and between groups. Logistic regression analysis was undertaken to determine the correlation of these parameters with VA recovery.Results: There was a significant reduction in DRA (P=0.007) and CMT levels (P=0.001) in both study groups after treatment. When the two groups were compared, the differences in pretreatment values of DRA (P=0.001), DRV (P=0.017), CMT (P=0.039), and mean BCVA (P=0.00) were found to be statistically significant. Posttreatment changes in DRA (P=0.013) and mean CMT (P=0.010) were found to be factors related to VA recovery by logistic regression analysis.Conclusion: Our findings reveal that ranibizumab treatment is associated with decrease in DRA, CMT, and significant improvement in VA recovery. Further, taking into account the cases in which VA was preserved, when needed, ranibizumab should be re-injected after the loading dose. Keywords: vessel caliber, prognosis, central macular thickness, retinal vein diameter, retinal arteriole diameterGungel HOsmanbasoglu OAAltan CBaylancicek DOPasaoglu IBDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 981-988 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Gungel H Osmanbasoglu OA Altan C Baylancicek DO Pasaoglu IB The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
description	Hulya Gungel,1 Ozen Ayranci Osmanbasoglu,1 Cigdem Altan,2 Deniz Oygar Baylancicek,3 Isil Basgil Pasaoglu2 1Istanbul Education and Research Hospital, Eye Clinic, 2Beyoglu Eye Education and Research Hospital, 3Kudret Eye Hospital, Istanbul, Turkey Aim: The objective of the study reported here was to evaluate the effect of ranibizumab on retinal circulation times and vessel caliber and to analyze the correlation of these factors with visual acuity (VA) prognosis in patients with age-related macular degeneration (AMD).Subjects and methods: This prospective cohort study included 52 eyes of 46 patients (mean age 73.5 years [standard deviation 7.7]; 28 males, 18 females). The study parameters were best-corrected visual acuity (BCVA), central macular thickness (CMT) (pre- and posttreatment: for 3 months after the last injection), retinal circulation times, diameter of retinal arteriole (DRA), and diameter of retinal vein (DRV) (pre- and posttreatment: after a loading dose of three consecutive injections of ranibizumab with a 4-week interval in the initial phase). The pretreatment, posttreatment measurements, and their differences were recorded for analyses. The injections were repeated when needed. Eyes were grouped into one of two groups according to VA recovery: Group 1, cases showing significant recovery of VA (n=21, 37%), and Group 2, cases showing preservation of VA (n=22, 42%) and deterioration of VA (n=11, 21%). Differences were compared statistically in and between groups. Logistic regression analysis was undertaken to determine the correlation of these parameters with VA recovery.Results: There was a significant reduction in DRA (P=0.007) and CMT levels (P=0.001) in both study groups after treatment. When the two groups were compared, the differences in pretreatment values of DRA (P=0.001), DRV (P=0.017), CMT (P=0.039), and mean BCVA (P=0.00) were found to be statistically significant. Posttreatment changes in DRA (P=0.013) and mean CMT (P=0.010) were found to be factors related to VA recovery by logistic regression analysis.Conclusion: Our findings reveal that ranibizumab treatment is associated with decrease in DRA, CMT, and significant improvement in VA recovery. Further, taking into account the cases in which VA was preserved, when needed, ranibizumab should be re-injected after the loading dose. Keywords: vessel caliber, prognosis, central macular thickness, retinal vein diameter, retinal arteriole diameter
format	article
author	Gungel H Osmanbasoglu OA Altan C Baylancicek DO Pasaoglu IB
author_facet	Gungel H Osmanbasoglu OA Altan C Baylancicek DO Pasaoglu IB
author_sort	Gungel H
title	The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
title_short	The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
title_full	The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
title_fullStr	The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
title_full_unstemmed	The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
title_sort	effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/59bab0f174834088b532509789749b02
work_keys_str_mv	AT gungelh theeffectsofranibizumabinjectionsonfluoresceinangiographicfindingsandvisualacuityrecoveryinagerelatedmaculardegeneration AT osmanbasogluoa theeffectsofranibizumabinjectionsonfluoresceinangiographicfindingsandvisualacuityrecoveryinagerelatedmaculardegeneration AT altanc theeffectsofranibizumabinjectionsonfluoresceinangiographicfindingsandvisualacuityrecoveryinagerelatedmaculardegeneration AT baylancicekdo theeffectsofranibizumabinjectionsonfluoresceinangiographicfindingsandvisualacuityrecoveryinagerelatedmaculardegeneration AT pasaogluib theeffectsofranibizumabinjectionsonfluoresceinangiographicfindingsandvisualacuityrecoveryinagerelatedmaculardegeneration AT gungelh effectsofranibizumabinjectionsonfluoresceinangiographicfindingsandvisualacuityrecoveryinagerelatedmaculardegeneration AT osmanbasogluoa effectsofranibizumabinjectionsonfluoresceinangiographicfindingsandvisualacuityrecoveryinagerelatedmaculardegeneration AT altanc effectsofranibizumabinjectionsonfluoresceinangiographicfindingsandvisualacuityrecoveryinagerelatedmaculardegeneration AT baylancicekdo effectsofranibizumabinjectionsonfluoresceinangiographicfindingsandvisualacuityrecoveryinagerelatedmaculardegeneration AT pasaogluib effectsofranibizumabinjectionsonfluoresceinangiographicfindingsandvisualacuityrecoveryinagerelatedmaculardegeneration
_version_	1718396047475081216

The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration

Ejemplares similares